Nurse's perspective on PARP inhibitors and personalised medicine in prostate can...
Louisa Fleure - Guy's and St Thomas' NHS Trust, London, UK
17 Feb 2021
TALAPRO-1: phase II study of talazoparib in patients with DNA damage repair alte...
Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
15 Feb 2021
ASCO GU 2021: Renal cancer roundup
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
15 Feb 2021
TITAN: Update and where next for patients with hormone sensitive PC
Prof Axel Merseburger and Prof Kim Chi
15 Feb 2021
OncoAlert and ecancer weekly roundup for February 07 - 13, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
15 Feb 2021
OncoAlert and ecancer weekly roundup for February 01 - 06, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
9 Feb 2021
Emergence of PARP inhibitors in prostate cancer
Kenrick Ng - Senior Specialist Registrar in Medical Oncology, UCL Hospitals, Lon...
5 Feb 2021
Advances and treatment strategies for metastatic hormone-sensitive prostate canc...
Kenrick Ng - Senior Specialist Registrar in Medical Oncology, UCL Hospitals, Lon...
5 Feb 2021
Outcomes of black and white men with prostate cancer in an equal access healthca...
Kenrick Ng - Senior Specialist Registrar in Medical Oncology, UCL Hospitals, Lon...
5 Feb 2021
OncoAlert and ecancer weekly roundup for January 25 - 31, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
4 Feb 2021
The role of a physician assistant in oncology
Noam Shabani - Dana-Farber Cancer Institute, Boston, USA
3 Feb 2021
Role of PARP inhibitors in treating advanced prostate cancer
Noam Shabani - Dana-Farber Cancer Institute, Boston, USA
3 Feb 2021
